Acta Scientific Microbiology (ISSN: 2581-3226)

Short Communication Volume 4 Issue 10

COVID-19 Vaccination in Cancer Patients

Attapon Cheepsattayakorn1,2*, Ruangrong Cheepsattayakorn3 and Porntep Siriwanarangsun1

1Faculty of Medicine, Western University, Pathumtani Province, Thailand
210thZonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: August 27, 2021 ; Published: September 08, 2021

  In patients with cancer, SARS-CoV-2 (COVID-19) can contribute to increasing morbidity and mortality [1-3] and decreased survival was found in patients with hematological and intrathoracic malignancies, poor performance status, comorbidities, and increased age [3-5]. Patients with hematological malignancies who were treated with stem cell transplantation and anti-CD-20 antibody demonstrated lower rates of seroconversion, compared to COVID-19-infected-cancer patients [6,7]. Patients with hematological malignancies might have substantially compromised B-cell and T-cell responses [8]. These study results indicated that following COVID-19 vaccination, overall high seroconversion rates could be anticipated in cancer patients due to different mechanisms and degrees of immune suppression, such as cell therapies (particularly chimeric antigen receptor (CAR)-T cell), anti-CD-20 antibody (B-cell depleting) therapies, stem cell transplantation, immunosuppressive effects of corticosteroid treatment, and cytotoxic-chemotherapy-bone-marrow-suppressive effects in certain subgroups of cancer patients [9]. Currently, there are lacking data in cancer patients in protection following SARS-CoV-2 (COVID-19) infection, reinfection by various SARS-CoV-2 (COVID-19) variants, or COVID-19 vaccination although mucosal surface antigens (e.g. IgA and protective T-cell responses) might be similarly important in protection from natural SARS-CoV-2 (COVID-19) infection [10]. The association of carcinogenesis with genomic information encoding vaccines, particularly with very-transient-intracellular-presence-COVID-19-mRNA vaccines is likely very low [11].


  1. Bakouny Z., et al. “CD8+ T cells contribute to survival in patients with COVID-19 and cancer: current challenges and perspectives”. Cancer Cell 38 (2020): 629-646.
  2. Kuderer NM., et al. “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study”. Lancet 395 (2020): 1907-1918.
  3. Mehta V., et al. “Case fatality rate of cancer patients with COVID-19 in a New York hospital system”. Cancer Discovery 10 (2020): 935-941.
  4. Grivas P., et al. “Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium”. Annals of Oncology 32 (2021): 787-800.
  5. Robilotti EV., et al. “Determinants of COVID-19 disease severity in patients with cancer”. Nature Medicine 26 (2020): 1218-1223.
  6. Marra A., et al. “Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2”. Annals of Oncology 32 (2020): 113-119.
  7. Thakkar A., et al. “Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy”. Nature Cancer 2 (2021): 392-399.
  8. Chamilos G., et al. “Are all patients with cancer at heightened risk for severe coronavirus disease 2019 (COVID-19)?” Clinical Infectious Disease2 (2021): 351-356.
  9. Thakkar A., et al. “Seroconversion rates following COVID-19 vaccination among patients with cancer”. Cancer Cell 39 (2021): 1-10.
  10. Korompoki E., et al. “COVID-19 vaccines in patients with cancer-a welcome addition, but there is need for optimization”. JAMA Oncology (2021): E1-E2.
  11. Górecki DC and Simons JP. “The dangers of DNA vaccination”. Nature Medicine2 (1999): 126.
  12. Kang CK., et al. “Cell-mediated immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors”. Journal of Infectious Disease11 (2020): 1902-1909.
  13. Fanciullino R., et al. “COVID-19 vaccine race: watch your step for cancer patients”. British Journal of Cancer5 (2021): 860-861.
  14. Desai A., et al. “COVID-19 vaccine guidance for patients with cancer participating in oncology Clinical Trials”. Nature Reviews Clinical Oncology 18 (2021): 313-319.
  15. Waissengrin B., et al. “Short-term safety on the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors”. Lancet Oncology 22 (2021): 581-583.
  16. Friese CR., et al. “Care without a compass: including patients with cancer in COVID-19 studies”. Cancer Cell (2021).
  17. Hwang JK., et al. “COVID-19 vaccines for patients with cancer : benefit likely outweigh risks”. Journal of Hematology and Oncology 14 (2021): 38.


Citation: Attapon Cheepsattayakorn.,et al. “COVID-19 Vaccination in Cancer Patients”. Acta Scientific Microbiology 4.10 (2021): 21-22.


Copyright: © 2021 Attapon Cheepsattayakorn.,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate33%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US